S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Our #1 Laser Stock for May (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
Is This The End Of Your Retirement? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Is This The End Of Your Retirement? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Our #1 Laser Stock for May (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
Is This The End Of Your Retirement? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Is This The End Of Your Retirement? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Our #1 Laser Stock for May (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
Is This The End Of Your Retirement? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Is This The End Of Your Retirement? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
Our #1 Laser Stock for May (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
Is This The End Of Your Retirement? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Is This The End Of Your Retirement? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:CHEK

Check-Cap (CHEK) Stock Forecast, Price & News

$1.46
-0.01 (-0.68%)
(As of 05/26/2023 ET)
Compare
Today's Range
$1.41
$1.49
50-Day Range
$1.30
$3.03
52-Week Range
$1.22
$9.20
Volume
17,775 shs
Average Volume
42,893 shs
Market Capitalization
$7.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Check-Cap MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
379.5% Upside
$7.00 Price Target
Short Interest
Healthy
0.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Check-Cap in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.80) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars


CHEK stock logo

About Check-Cap (NASDAQ:CHEK) Stock

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.

Receive CHEK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Check-Cap and its competitors with MarketBeat's FREE daily newsletter.

CHEK Stock News Headlines

Is This The End Of Your Retirement?
Soon, the U.S. Government is going to make an announcement that could radically alter your retirement. Two of America's largest banks - Goldman Sachs and J.P. Morgan - have quietly warned their richest clients to prepare for it. The clock is ticking. Find out How to Protect Yourself from the Greatest Crisis Facing Retirees in 70 Years before it's too late.
Check-Cap (CHEK) Gets a Buy from H.C. Wainwright
Check-Cap (NASDAQ:CHEK) Now Covered by StockNews.com
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Check-Cap GAAP EPS of -$0.76 misses by $0.02
Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com
StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)
Check-Cap Issues an Update to Shareholders
Why Are Check-Cap Shares Plummeting Today?
Fact-checking Liz Truss at PMQs - BBC
See More Headlines
Receive CHEK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Check-Cap and its competitors with MarketBeat's FREE daily newsletter.

CHEK Company Calendar

Last Earnings
3/31/2023
Today
5/28/2023
Next Earnings (Estimated)
8/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
X-ray apparatus & tubes
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHEK
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+379.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-19,110,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.68 per share

Miscellaneous

Free Float
4,798,000
Market Cap
$7.04 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Alex Ovadia
    Chief Executive Officer
  • Joshua Belkar
    Vice President-Operations
  • Mira Rosenzweig
    Chief Financial Officer
  • Yoav Kimchy
    Chief Technology Officer
  • Boaz Shpigelman
    Vice President-Research & Development













CHEK Stock - Frequently Asked Questions

Should I buy or sell Check-Cap stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Check-Cap in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHEK shares.
View CHEK analyst ratings
or view top-rated stocks.

What is Check-Cap's stock price forecast for 2023?

2 equities research analysts have issued twelve-month price targets for Check-Cap's shares. Their CHEK share price forecasts range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 379.5% from the stock's current price.
View analysts price targets for CHEK
or view top-rated stocks among Wall Street analysts.

How have CHEK shares performed in 2023?

Check-Cap's stock was trading at $2.20 on January 1st, 2023. Since then, CHEK shares have decreased by 33.6% and is now trading at $1.46.
View the best growth stocks for 2023 here
.

Are investors shorting Check-Cap?

Check-Cap saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 50,900 shares, an increase of 226.3% from the April 30th total of 15,600 shares. Based on an average daily trading volume, of 63,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.9% of the shares of the company are short sold.
View Check-Cap's Short Interest
.

When is Check-Cap's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 30th 2023.
View our CHEK earnings forecast
.

How were Check-Cap's earnings last quarter?

Check-Cap Ltd. (NASDAQ:CHEK) released its earnings results on Friday, March, 31st. The medical research company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.04.

When did Check-Cap's stock split?

Check-Cap's stock reverse split on the morning of Friday, November 25th 2022. The 1-20 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Check-Cap own?
When did Check-Cap IPO?

(CHEK) raised $13 million in an IPO on Thursday, February 19th 2015. The company issued 1,200,000 shares at a price of $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group served as the underwriters for the IPO and Feltl and Company was co-manager.

What is Check-Cap's stock symbol?

Check-Cap trades on the NASDAQ under the ticker symbol "CHEK."

Who are Check-Cap's major shareholders?

Check-Cap's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (1.31%) and Susquehanna International Group LLP (0.83%).

How do I buy shares of Check-Cap?

Shares of CHEK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Check-Cap's stock price today?

One share of CHEK stock can currently be purchased for approximately $1.46.

How much money does Check-Cap make?

Check-Cap (NASDAQ:CHEK) has a market capitalization of $7.04 million. The medical research company earns $-19,110,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How can I contact Check-Cap?

Check-Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The official website for the company is www.check-cap.com. The medical research company can be reached via phone at 972546706451, via email at jeremy@lifesciadvisors.com, or via fax at 972-4821-1267.

This page (NASDAQ:CHEK) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -